Írland - enska - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - granisetron hydrochloride - concentrate for solution for injection - 3mg/3ml - serotonin (5ht3) antagonists; granisetron

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - granisetron hydrochloride, quantity: 1.12 mg/ml (equivalent: granisetron, qty 1 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; citric acid monohydrate; sodium chloride; water for injections; sodium hydroxide - adults: kytril (tablets and injection) is indicated for use in adults for: the prevention of nausea and vomiting induced by cytotoxic chemotherapy; the prevention of nausea and vomiting induced by radiotherapy. kytril (injection) is also indicated for use in the treatment of nausea and vomiting induced by cytotoxic chemotherapy; and prevention and treatment of post-operative nausea and vomiting.,paediatric: kytril injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy..

Bandaríkin - enska - NLM (National Library of Medicine)

northstar rx llc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride tablets are indicated for the prevention of: - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.

Bandaríkin - enska - NLM (National Library of Medicine)

bionpharma inc. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride tablets are indicated for the prevention of: - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fresenius kabi espaÑa, s.a.u. - granisetron hidrocloruro - concentrado para soluciÓn inyectable - 3 mg - granisetron hidrocloruro 1 mg - granisetrón

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

devatis limited - granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg - solution for injection - 1 mg/ml - active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg excipient: citric acid monohydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy in adults for the prevention of nausea and vomiting induced by cytotoxic chemotherapy in children

Malta - enska - Medicines Authority

actavis group ptc ehf - granisetron hydrochloride - coated tablet - granisetron hydrochloride 1.12 mg - antiemetics and antinauseants

Malta - enska - Medicines Authority

actavis group ptc ehf - granisetron hydrochloride - coated tablet - granisetron hydrochloride 2.24 mg - antiemetics and antinauseants

Malta - enska - Medicines Authority

sigillata limited - granisetron hydrochloride - film-coated tablet - granisetron hydrochloride 1.12 milligram(s) - antiemetics and antinauseants

Malta - enska - Medicines Authority

sigillata limited - granisetron hydrochloride - film-coated tablet - granisetron hydrochloride 2.24 milligram(s) - antiemetics and antinauseants